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same variety ofsoybeans grown in different
locations (25,26). Also, in closed formula
diets containing soybeans, the concentra-
tion ofsoybeans in the diet is not reported
and may vary from batch to batch depend-
ing upon the supply and demand ofdietary
ingredients. This could explain why the
phytoestrogen content of diets may vary
greatly from batch to batch or from the
same diet processed by different rodent diet
vendors. These findings support the need
to use open formula diets prepared from
controlled ingredients and the need to
monitor these diets for estrogenic sub-
stances that affect biological end points. We
also agreewith Boettger-Tong et al. (1) that
rodent diet vendors do not routinely moni-
tor all diets for estrogenic substances
including phytoestrogens. Rodent diet ven-
dors producing certified diets for use in
comparative estrogenicity and carcinogenic-
ity studies should provide the user with a
list ofsubstances assayed, including phytoe-
strogens, and the results. In our opinion,
diets used in comparative estrogenicity or
carcinogenicity studies should contain non-
detectable levels of estrogenic substances
that may alter research results. These diets
should be monitored for estrogenic sub-
stances and their concentrations reported.
The commentary by Boettger-Tong et
al. (1) is important because the authors
emphasize the important role of the ani-
mal's diet, especially phytoestrogens, when
conducting animal bioassays for estrogenici-
ty or studies that are influenced by in vivo
end points of hormone action. We previ-
ously reported that rodent diets significantly
differ in estrogenic activity and that a stan-
dardized diet with minimal estrogenic activ-
ity would be desirable for comparative
bioassays for estrogenic substances (5).
Results from our second study (20) confirm
that astandardized open formula diet should
be used for studies that are influenced by
exogenous estrogens (4,5). Phytoestrogens
were not detected in the AIN-76A and the
AIN-93M purified casein diets. Therefore,
careful consideration should be given to the
use of diets such as these when conducting
studies that are influenced by exogenous
estrogens. We have also shown that a natural
ingredient diet can be formulated to contain
less than detectable levels ofthe phytoestro-
gens (daidzein and genistein) by omitting
soybean and alfalfa meals. The soybean and
alfalfa meals were omitted because they may
be a source of multiple, yet unidentified,
phytoestrogens that may further complicate
the interpretation of results from studies
which are influenced by exogenous estro-
gens. We recommend that studies to deter-
mine the effects ofdietary phytoestrogens on
results of toxicloOgiC investigations are
important and timely. National Toxicology
Program studies that will help us understand
the effect oflong-term feeding ofa diet with
less than detectable levels of daidzein and
genistein are presendy underway.
In conclusion, we recommend that
careful consideration be given to the phy-
toestrogen content of the diet when con-
ducting studies that are influenced by
exogenous estrogens. A standardized open
formula diet in which estrogenic substances
have been reduced to minimal levels or to
less than detectable levels of daidzein and
genistein is recommended for use in such
studies. In addition, the selected diet should
be monitored for estrogenic substances, and
their concentrations should be reported.
Julius E. Thigpen
Kenneth D. R. Setchell
Mary F. Goelz
Diane B. Forsythe
NIEHS
Research Triangle Park, North Carolina
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The TEF Approach for
Hexachlorobenzene
Van Birgelen (1) argues that hexachloroben-
zene (HCB) has dioxinlike activity to the
extent that its toxicity may be evaluated
using a so-called toxic equivalency factor
(TEF), which treats the toxic potency of
HCB as a fraction ofthe potency of2,3,7,8-
tetrachloro-p-dibenzodioxin (TCDD). She
suggests a TEF of0.0001 based on compar-
isons of in vitro effects including binding
affinity for the aryl hydrocarbon (Ah) recep-
tor and effective concentrations for
ethoxyresorufin O-dethylase induction and
uroporphyrin accumulation in chicken
hepatocytes. Van Birgelen (1) reported that
these measures were used because "no in
vivo studies designed for estimating a TEF
value are available." This may come as
something ofa surprise to researchers at the
EPA, who derived a potency factor (PF) for
the carcinogenic activity of HCB based on
studies of hepatocellular carcinoma in
female Sprague Dawley rats (2) using a pro-
tocol similar to the one that supports earlier
estimates of the carcinogenic activity of
TCDD (3). The EPA reports that the upper
95th percent confidence bound on the slope
fitting the HCB data to a linearized multi-
stage model ofcarcinogenesis is 1.6 per mil-
ligram of HCB per kilogram body weight
per day (mg/kg/day) (4).
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There is no PF for TCDD currently
available in the Integrated Risk Information
Service database (3). However, the PF origi-
nally derived from the aforementioned
study was 156,000 mg/kg/day and may be
modified downward to approximately
100,000 mg/kg/day, based on reinterpreta-
tion of histopathologic data. Applying van
Birgelen's TEF to these values would sug-
gest a PF for the carcinogenic action of
HCB (under the linearized multistage
assumptions) to be approximately 10-16
mg/kg/day, or about an order ofmagnitude
more potent than issuggested by the in vivo
data. It is possible that the difference lies in
pharmacokinetic or pharmacodynamic fac-
tors that exist in the whole animal, which
cannot becaptured incellular assays.
As van Birgelen points out (1), the
World Health Organization indicates a
preference for long-term in vivo studies
over in vitro measures when setting a TEF
(5). The HCB example illustrates the
extreme caution that should be exercised
when applying a TEF based solely on in
vitro information, particularly when major
public health claims are being made.
BradleyW. Schwab
Ogden Environmental and Energy
Services Company
Westford, Massachusetts
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Response:
Hexachlorobenzene
I appreciate Schwab's comments regarding
caution in the use of a toxic equivalency
factor (TEF) for hexachlorobenzene
(HCB) based on results of in vitro studies.
The dioxinlike effects of HCB include
cytochrome P4501A induction and bind-
ing to the aryl hydrocarbon (Ah) receptor.
In addition, HCB has been shown to
bioaccumulate. These three factors are a
prerequisite to include a compound in the
TEF concept, which compares the potency
ofa dioxinlike compound to 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD). TEFs
are consensus values based on available
data on relative potency values for specific
compounds (1). TEF values are used to
estimate the total dioxin activity in envi-
ronmental and human samples by multi-
plying the TEF value by the concentration
of each compound, leading to a certain
amount of toxic equivalents (TEQs) for
each compound. The summation of all
TEQs in a certain mixture expresses the
total dioxin activity ofthis mixture. Based
on the binding affinity of HCB to the Ah
receptor, in vitro cytochrome P4501A
induction, and porphyrin accumulation, a
relative potency of 0.0001 for HCB was
estimated (X). Using this relative potency
value suggested that HCB could lead to a
considerable contribution to the dioxin
activity ofhuman milk in some countries.
I did not estimate the slope factor for HCB
that is used in carcinogenicity assessment.
The slope factor is the result ofthe applica-
tion ofa low-dose extrapolation procedure
and is presented as the risk per milligram
per kilogram of body weight per day
(mglkg/day) (3).
Schwab's comments included the com-
parison of these slope factors (although
potency factors are mentioned) for HCB
(1.6 per mg/kg/day) and TCDD (100,000
or 156,000 per mglkg/day). The slope fac-
tors for TCDD are not available in the
Integrated RiskInformation Service database
(3), as Schwab mentioned. He points out
correctly that the ratio between these two
slope factors is different from the suggested
relative potencyvalue for HCB. He assumes
byusing this approach thatTEFs would pre-
dict the carcinogenic potential ofdioxinlike
compounds. However, no studies have been
performed to verify this approach. Studies
are currently under way to determine
whether relative potency values based on
biochemical effects are predictive for car-
cinogenesis in female Sprague Dawley rats
forvarious dioxinlike compounds (4).
Angilique PJ.M. van Birgelen
NIEHS
Research Triangle Park, North Carolina
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